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 Introduction 
 Access to drugs that do not have approval for marketing by the US 
Food and Drug Administration (FDA) was recently brought to the 
forefront of public awareness. From a popular Hollywood movie to 
numerous compelling stories of individuals who have attempted 
to obtain experimental treatments, the issue has become both a 
media and legislative focus. 1–3 Four state legislatures—Colorado, 
Louisiana, Missouri, and Michigan—have passed “Right-to-Try” 
bills that include provisions to circumvent FDA approval for use of 
unapproved drugs. 4–7 Arizona voters passed a similar referendum. 8 
Additional legislation has been proposed at both the State and 
Federal levels. 9 Given this increased public awareness, it is likely 
that many physicians, particularly those caring for patients with 
life-threatening illnesses, for example cancer, infectious disease, 
or neurologic conditions, will encounter questions about access to 
investigational drugs. In this review we present information about 
both the FDA’s Expanded Access (EA) program 10 and “Right-to-
Try” legislation including a comparison of key elements. Th is 
review also provides direction and resources to the physician 
and the institution for working within FDA regulations. Th is 
approach can not only provide patient access to new drugs, 
but also maintains necessary patient protections and permits 
continued data collection for future users of the product. 
 Legislation and Regulations 
 “Right-to-Try” legislation 
 Th e impetus for the so-called “Right-to-Try” legislation has been 
fueled by a spate of stories chronicling terminally ill patients who 
were denied access to experimental drugs. 1–3 Th ese new laws 
allow physicians and patients to bypass FDA review and approval 
and do not require review by an ethics committee for the use of 
experimental treatments. Moreover, these bills do not provide 
any requirement for pharmaceutical companies to (1) provide the 
product, (2) set up a clinical study to test the product, (3) change 
the inclusion and exclusion criteria for current clinical studies, (4) 
provide product at an aff ordable price, or (5) incentivize insurance 
companies to cover the cost of the product. Also included in 
most of the legislation is a requirement for the patient to sign 
an informed consent form, but the adequacy of the disclosure is 
not reviewed. Most of the bills also include indemnifi cation as 
well as exculpatory language for the informed consent document, 
which is contrary to usual standards for informed consent. 11,12 
Table  1 provides a comparison of key diff erences in the existing 
FDA program and the proposed statutory language for “Right-
to-Try” legislation. 1 
 EA to investigational drugs 
 Much of the proposed legislation as well as public commentary on 
the topic reveal a profound lack of understanding about the existing 
means to obtain investigational treatments. 2,13 Currently, the FDA’s 
EA program (see Box 1 for a summary) seeks to strike a balance in 
providing access to unapproved drugs and treatments, protecting 
patients from unreasonable toxicity or danger, and collecting 
safety data from patients as they take new medications. 14,15 EA, 
sometimes informally referred to as “Compassionate Use,” is 
diff erent from a standard investigational drug study in that it is 
not primarily intended to obtain safety and effi  cacy data but was 
specifi cally written to allow use of these agents for treatment of 
patients outside of a clinical trial in a prescribed manner. 14 Th e 
FDA EA program receives about 1,000 EA requests per year and 
approves over 99% of such requests (Figure  1 ). 16 Th is should not 
be interpreted that all requests for such access are always granted. 
 Access to Investigational Drugs: FDA Expanded Access Programs or 
“Right-to-Try” Legislation? 
 M. E. Blair  Holbein ,  Ph.D., B.C.A.P. 1 ,  Jelena P.  Berglund ,  Ph.D., R.A.C. 2 ,  Kevin  Weatherwax ,  C.C.R.C., C.C.R.A. 3 ,  David E.  Gerber ,  M.D. 1 , 
 and  Joan E.  Adamo ,  Ph.D. 4 
 Special Reports 
 1 Center for Translational Medicine, UT Southwestern Medical Center ,  Dallas ,  Texas ,  USA ;  2 Duke Translational Medicine Institute ,  Durham ,  North Carolina ,  USA ;  3 Michigan Institute 
for Clinical and Health Research ,  University of Michigan Health System ,  Ann Arbor ,  Michigan ,  USA ;  4 Clinical & Translational Science Institute, University of Rochester Medical Center , 
 Rochester ,  New York ,  USA . 
 Correspondence: M.E. Blair Holbein ( Blair.Holbein@UTSouthwestern.edu ) 
 DOI:  10.1111/cts.12255 
 Abstract 
 Purpose:  The Food and Drug Administration Expanded Access (EA) program and “Right-to-Try” legislation aim to provide seriously ill 
patients who have no other comparable treatment options to gain access to investigational drugs and biological agents. Physicians and 
institutions need to understand these programs to respond to questions and requests for access. 
 Methods:  FDA EA programs and state and federal legislative efforts to provide investigational products to patients by circumventing 
FDA regulations were summarized and compared. 
 Results:  The FDA EA program includes Single Patient-Investigational New Drug (SP-IND), Emergency SP-IND, Intermediate Sized 
Population IND, and Treatment IND. Approval rates for all categories exceed 99%. Approval requires FDA and Institutional Review Board 
(IRB) approval, and cooperation of the pharmaceutical partner is essential. “Right-to-Try” legislation bypasses some of these steps, but 
provides no regulatory or safety oversight. 
 Conclusion:  The FDA EA program is a reasonable option for patients for whom all other therapeutic interventions have failed. The SP-
IND not only provides patient access to new drugs, but also maintains a balance between immediacy and necessary patient protection. 
Rather than circumventing existing FDA regulations through proposed legislation, it seems more judicious to provide the knowledge 
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 Expanded access to investigational drugs for treatment 
use 21 CFR 312.300 (single patients 21 CFR 312.310) 
“Right-to-Try” proposed statutory language from 
 Goldwater Institute 
Oversight FDA No agency or board oversight 
 Institutional Review Board 21 CFR 312.305(c)(4) No requirement for independent review 
Eligible 
patient 
“Serious or immediately life-threatening disease or 
 condition” with no comparable or satisfactory alternative 
 therapy 21 CFR 312.300(b) 
Terminal disease (an advanced stage of a disease with 
an unfavorable prognosis and no known cure) 
 The physician determines that the probable risk to the 
person from the investigational drug is not greater than the 
probable risk from the disease or condition 
The physician gives a prescription or recommendation 
for an investigational drug, biological product, or 
device; and in consultation with the patient 
considers all other  treatment options currently 
approved by the FDA 
 FDA determines if the potential patient benefi t justifi es the 
potential risks of the treatment use and those potential 
risks are not unreasonable in the context of the disease or 
condition to be treated 
 
Duration Treatment usually limited to a single course or specifi ed 
 duration of therapy unless otherwise authorized 21 CFR 
312.10(c)(1) 
No limits stated 
Accountability Physician (Investigator/Sponsor-Investigator) obtains IRB 
approval, informed consent, reports adverse events, main-
tains accurate case histories, drug disposition records, and 
at the end of therapy submits a summary report to FDA. 21 
CFR 312.05(c); 21 CFR 312.10(c)(1) 
Physician obtains informed consent. 
Informed Con-
sent 
Required. CFR 50.25 (parallels CFR 46.116 Protection of 
Human Subjects) 8 required and 6 possible additional 
elements 
Required no prescribed content. Notable exception: 
Colorado and Michigan have seven required elements 
 IRB reviews and approves the informed consent 
document assuring accuracy, understandability, and 
 completeness 
No review specifi ed 
Costs Manufacturer may charge if CFR 312.8(c) parameters met; 
FDA must approve 
Manufacturer may charge 
 No requirement for insurance company or governmental 
heath care program to provide coverage 
No requirement for insurance company or 
 governmental heath care program to provide coverage 
Liability Not addressed Bars action by medical licensing boards against 
 prescribing physician based on recommendation of 
investigational agent. 
  Criminalizes blocking access to the investigational 
agent (misdemeanor) 
  Note, Colorado and Michigan legislation includes 
 additional indemnifi cation for the manufacturer of the 
investigational agent. 
Investigational 
drug defi nition 
New drug or biological drug that is used in a clinical 
 investigation 
Drug, biological product or device which has 
successfully completed Phase 1 of clinical trials, 
but has not been approved for general use by the 
FDA and must currently be under investigation in an 
FDA clinical trial 
Drug/device 
quality 
Manufacturing standards established and reviewed in the 
IND. 21CFR 312.305(b)(2)(vi), (vii) 
Not addressed 
Drug/device 
information 
If available, an investigator’s brochure with information 
from the manufacturer about drug administration and 
monitoring for known toxicities and adverse effects pro-
vided to the treating physician and IRB of record 
Not addressed 
Drug/device 
availability 
Determined by manufacturer; not mandated Determined by manufacturer; not mandated 
Impact on future 
research 
Provision of the investigational drug should not  interfere 
with the initiation, conduct or completion of clinical 
 investigations that could support marketing approval or 
development of the agent. 21 CFR 312.305 (a)(1) 
Not addressed 
Timeframe Emergency: hours to days; 30-day window on IND but 
 usually shorter 
No delay 
 Table 1.  Comparison between the FDA expanded access to investigational drug as applies to individual patients and the proposed “Right-to-Try” statutory language (Goldwater 
Institute). 
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While the FDA tries to accommodate the needs of the patient, 
occasionally there are variations in the acceptable risks that might 
not be apparent to the public. Th e FDA has access to safety data and 
has expertise to make assessments as to “reasonableness” of the 
proposed use. Th e FDA oft en works closely with the manufacturer 
to avail the product to the patient under these circumstances. 13,17 
Nevertheless, in some instances—despite FDA approval—the 
company owning the product may decline to provide it outside 
the context of a formal clinical study. 
 Patient eligibility and roles for EA 
 Th e FDA has clear regulations that defi ne patient eligibility for 
the EA program. Th e criteria generally include patients with an 
immediately life-threatening disease or condition with a substantial 
risk of mortality or premature death occurring within a window 
of months and who have no satisfactory alternative therapy to 
diagnose, monitor, or treat the disease or condition. 10 Th e EA 
process has several means of access and multiple submission 
pathways. Table   2 provides the defi ning criteria, including the 
number of patients to be treated, potential access to an existing 
study being conducted under an Investigational New Drug (IND) 
application and whether there is a need for emergency treatment. 
Applications that are made under current INDs are mediated 
through the IND sponsor who for novel therapies is usually the 
manufacturer. In these cases the use is obtained by an amendment 
to an existing IND and is referred to as a “protocol amendment 
IND.” Alternatively, when one person takes on the roles of both the 
regulatory “Sponsor” as defi ned by the FDA and as the physician 
who administers the investigational drug, he or she becomes a 
“Sponsor–Investigator,” a role which includes the analysis of the 
lack of therapeutic options, fi ling the IND, as well as obtaining 
the approval of an Institutional Review Board (IRB). Importantly, 
for Sponsor–Investigators additional regulatory obligations such 
as ongoing reporting to the FDA do not end until the IND is 
withdrawn. 18 Figure  2 provides a fl owchart to guide the physician 
regarding which type of submission pathway is most applicable. 
 EA for an individual patient through the Single Patient-IND 
 In both academic health centers and in community-based 
physician practices, the most frequently encountered EA 
category is the Single Patient-IND (SP-
IND) application. Enrollment of a patient 
in a clinical trial may not possible due to 
geographic location, stringent eligibility 
criteria, or timing of the trial. In such cases, 
through the SP-IND mechanism, the FDA 
permits an investigational drug to be used 
for the treatment of an individual patient 
suff ering from serious or immediately life-
threatening disease or a condition for which 
there is no satisfactory approved therapy. 
Th e treatment under the SP-IND is generally 
limited to a single course of therapy for a 
specifi c duration, although the FDA may 
authorize multiple courses or chronic 
therapy. For example, treatment may be 
approved until either disease progression, 
intolerable toxicity, or patient/provider 
preference. Commercial availability may 
also result in an early conclusion of the 
IND. Th ere are both nonemergency and 
emergency versions of the SP-IND (Table  2 ). 
 Applying for a nonemergency 
SP-IND follows the standard IND 
application regulations (see Box 2, SP-IND 
Submission). 19 Th e essential fi rst step in an 
SP-IND is working with the manufacturer 
 Figure 1.  FDA expanded access program, activity reports data for single patient INDs shown. Filings for other 
expanded access INDs and protocols were much smaller in number and are not shown. Approval rate ex-
ceeded 99% for all other categories.13 Inclusive dates for reporting periods: 2010 (10/13/09–10/12/10), 2011 
(10/13/10–10/12/11), 2012 (10/01/11–09/30/12), 2013 (10/01/12–09/30/13). 
 Box 1. Expanded Access Summary 
 Expanded Access (EA), oft en called “Compassionate Use,” 
is a way to use an investigational drug or biologic that is 
not approved by the FDA and is given outside of a research 
study. Occasionally, there are situations where a patient 
with a serious or immediately life-threatening disease 
has no alternative treatment options. In these cases the 
investigational drug is expressly used for the treatment of 
patients and not for study of the drug. Under EA the FDA 
allows such use for either individual patients or for larger 
size groups. Th e process is governed by federal regulations 
(21 CFR part 312.300). 
 EA begins with agreement between the manufacturer/
sponsor to supply the drug and the treating physician. Th ese 
arrangements must be authorized by the FDA through an 
Investigational New Drug (IND) Application. Th e IND 
is a structured presentation of the information needed 
to use the drug in a human patient. Investigational drugs 
have signifi cant risks to the patient that must be taken into 
account and oversight by an Institutional Review Board 
(IRB or Ethics Committee) is also required. 
 Manufacturers  are not required to set up these EA 
protocols. Th ey are  not required to supply the drug nor 
manufacture more drugs to meet a larger need. 
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to obtain drug. Most of the product information needed in the 
IND is supplied as a reference to existing manufacturer-supplied 
data. Th e treating physician will have the necessary information 
about the patient readily available as part of the medical record. 
Although the statutory 30-day FDA review period applies, in 
many cases the process is expedited. Notably, all of the usual 
“life cycle” IND maintenance activities, such as safety and annual 
reporting as well as submission of amendments, still apply. 18 
 Emergency SP-INDs include life-threatening circumstances 
where no alternative is available and there is no time to prepare 
a written submission to the FDA. In these infrequent and 
extraordinary situations the physician may treat the patient prior 
to FDA notifi cation. Nevertheless, all attempts should be made 
(if time allows) to obtain any feedback from the FDA via phone, 
e-mail or fax before the treatment. 19,20 If time does not allow 
for any feedback, the physician is allowed to proceed with the 
Type of extended access 
(EA) IND  
21 CFR 
312.300 
Number of 
patients 
FDA 
review time 
IRB approval FDA  approval Course of 
therapy 
Single patient-IND/
protocol 
amendment 
Nonemer-
gency use 
§312.310 1 30 days Approval 
needed prior 
to treatment 
Approval 
needed prior 
to treatment 
Usually 1 
Emergency 
use 
§312.310(d) 1 Urgent Report within 
5 days 
Approval prior to 
treatment; report 
within 15 days 
Usually 1 
Intermediate size 
 patient population 
IND/protocol 
 amendment 
N/A §312.315 Smaller than 
typical Treatment 
IND (usually < 
100) 
30 days Approval 
needed prior 
to treatment 
Approval needed 
prior to treatment 
Defi ned in 
protocol 
Treatment IND/ 
protocol amendment 
N/A §312.320 Written into 
protocol 
30 days Prereported Prereported Defi ned in 
protocol 
 Notes: Under the FDA’s EA program, there are several regulatory strategies available and the best one to use will depend on the particular factors for each situation. This table 
lists some of the key factors to consider when choosing which strategy to employ. In each of the four types of EA pathways, the use of protocol amendment submitted to an 
existing IND is the most straight-forward and entails the least regulatory submission burden. 
 Table 2.  Characteristics of expanded access (EA) INDs. 
 Figure 2.  Flowchart for expanded access paths. 
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necessary investigational treatment and report it to the FDA later 
within the required time frame. 21 By utilizing the Emergency IND 
submission pathway, the FDA allows access of an investigational 
drug to the patient in an extremely short time period, while still 
providing necessary oversight. It is also important to note that 
this scenario which aims for the fastest available treatment, would 
equate to the Right-to-Try legislation, but maintains oversight 
and accountability. 
 EA for intermediate-size population and Treatment IND 
 When there are a number of individual patients with the same 
disease or condition, the FDA may ask the sponsor to consolidate 
SP-INDs under an intermediate-size patient population IND (21 
CFR 312.315). Th is might apply if the drug is not being actively 
developed, or if the patient population is too small, as in the 
case with rare diseases. As for all EA types of INDs, in order to 
be eligible for drug access under an intermediate-size patient 
population IND, the FDA must determine that the conditions 
listed in the regulations are met and that the risk/benefi t ratio has 
been assessed and justifi ed. Finally, if a drug has been removed 
from the market due to safety reasons, there might be a situation 
calling for an intermediate-size IND. 
 Th e Treatment IND allows patients to access a drug that is 
currently being reviewed under an FDA marketing application, 
but has not yet received FDA approval (21 CFR 312.320). Here 
safety and effi  cacy data have already been collected and submitted 
to the FDA and are undergoing review for marketing approval. A 
Treatment IND is sponsored by the company seeking marketing 
approval and can provide drug access to hundreds to thousands of 
patients while FDA review for fi nal approval is underway. Patients 
must still meet eligibility criteria, and during the course of the 
study data will continue to be collected and used to expand the 
current knowledge about the drug. 
 Using the access process 
 For both the physician and the patient it is essential to understand 
that the best access to an investigational drug is by participation 
in a clinical trial. Before considering EA, every eff ort should 
be made to fi nd a clinical trial for the patient through clinical 
trial databases (such as clinicaltrials.gov), working with patient 
advocacy groups, or making inquiries to the manufacturer or the 
FDA. Established clinical trials have been reviewed carefully to 
ensure the best utilization of the investigational drug and the 
most comprehensive ethics review. Also the most accurate and 
rigorous data collection will take place under a clinical trial to 
inform its use in other patients and to guide future indications. 
Not infrequently, this would also be the most timely and least 
costly route for the patient, as well as provide the most equitable 
access. 
 Pharmaceutical sponsors and EA 
 Th e necessary fi rst step in any EA process is to obtain access to the 
drug. Th e most direct approach is to contact the manufacturer. 
Research personnel from the manufacturer that the investigator 
has worked with previously may be able to expedite contact with 
the appropriate individuals at the manufacturer. Alternatively, 
most manufacturers have contact information on their Websites. 
In the case of a call to a manufacturer it is important to make clear 
the intent of the call is to contact the research personnel familiar 
with the test agent. In either case the physician should be able to 
readily provide information about the circumstances that make 
EA the best option for the patient. Th is includes the clinical status 
of the patient and the appropriateness of the test agent for that 
patient. Contact with the FDA may also expedite the process if 
attempts to contact the manufacturer are not successful. A list of 
contact phone numbers for the appropriate Offi  ce or Division is 
maintained on the FDA Website. 19 Sometimes the FDA can assist 
in the process of making drug available. Th ey may also help in 
guiding the investigator to provide the information needed by the 
FDA to understand the clinical status of the patient. 
 Institutional Review Boards and EA 
 Th e administration of any investigational drug under the auspices 
of an IND also requires approval by an IRB. 14 Because of their 
 Box 2. Expanded Access, Single Patient-IND Submission Contents 
1.   FDA Form 1571—structured presentation guide for the needed information. (Search “FDA Forms” to fi nd FDA Form 
Website). 
2.   Statement of the rationale for using the drug. Include a list of the available options and an explanation of why the investigational 
agent is preferable or the only therapeutic option. 
3.   Description of the individual patient’s disease or condition. Include medical history, description of previous treatments, and 
suffi  cient information to make the rationale for requesting the investigational clear. 
4.   Description of the intended method of administration of the drug including dose and duration of therapy. 
5.   Reference the manufacturer’s “Chemistry, Manufacturing, and Controls” information. Th is will require permission and 
cooperation of the manufacturer to provide this information, usually as a cross-reference to an existing FDA fi le. 
6.   Reference the manufacturer’s “Pharmacology and Toxicology Information.” Th is will require permission and cooperation 
of the manufacturer and usually cross-references an existing FDA fi le. 
7.   Description of plan to evaluate the eff ects of the drug and minimize the risks. Th is will include clinical procedures, laboratory 
tests, or clinical assessments as needed. Include the proposed patient Informed Consent document and the plan for monitoring 
for adverse eff ects. 
8.   FDA Form 1572—statement of the qualifi cations of the investigator (usually the treating physician). An academic curriculum 
vitae or the equivalent is suffi  cient. 
9.   Clearly mark the submission cover sheet and the mailing envelope as “EXPANDED ACCESS SUBMISSION.” 
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situation, patients with life-threatening conditions are a “vulnerable 
population” who especially need the protections provided by 
an IRB. A central role for the IRB is assisting the Sponsor–
Investigator in assuring that an adequate informed consent 
process occurs. To address a possible therapeutic misconception 
that the likelihood of the perceived benefi t is greater than it may 
actually be, the informed consent document should include an 
explicit statement of the experimental nature of the therapy, the 
unknown likelihood of benefi t and risk, and a comprehensive 
explanation of any alternative therapies. Some IRBs may not be 
familiar with the EA process and may not understand that the 
intent is explicitly treatment and not research. Th e choice of EA 
implies that the investigator has made a clinical judgment that 
the probable risk from the investigational drug is not greater than 
the probable risk from the disease or condition. 14 Th e IRB should 
rely on the assessment of the clinician as well as medical records 
included in the request as to the status of the patient and the 
immediacy of the need to treat. An important diff erence for an 
IRB to consider when reviewing an EA request is that information 
available about the investigational drug might be substantially 
less than would usually be available for IRB deliberations. Th e 
supporting data needed for use in a single patient with a life-
threatening condition is signifi cantly less than would be required 
for use in larger population IND. Th e risk-benefi t calculus that 
is usually an essential part of an IRB deliberation is markedly 
diff erent for an SP-IND. 
 Regulations currently require an IRB to conduct a full board 
review, which can present the possibility of administrative 
delays. However, IRBs at most major medical centers usually 
have a process in place for handling emergency as well as 
nonemergency SP-INDs in accordance with FDA regulations. 
In contrast, small or community-based healthcare system IRBs 
may not be familiar with the EA process; nor can they quickly 
assemble to review such a request. Th e possibility of developing 
reciprocity with a regional IRB, such as at an academic medical 
center within reasonable proximity, or taking part in a central 
IRB that has experience with such protocols may be an option 
for some sites. 22 
 Available resources for EA 
 Th ere are numerous resources available to assist in the preparation 
of the EA IND. Th e FDA maintains an easily navigable Website. 23 
Enlisting the help of regulatory specialists can greatly assist in 
understanding and completing the needed documentation. 
A survey of U.S. academic health centers across the country 
showed that the majority of them have offi  ces with dedicated 
IND specialists to assist with these processes. 24 Informal polling 
within these offi  ces indicates that nearly all provide specifi c 
services for EA INDs without charge. Finally, since IRB approval 
is needed, contact with the IRB of record should be made early 
in the process. 
 Discussion 
 The existing FDA EA program was specifically written to 
provide an effective means to access investigational drugs 
while maintaining a balance between subject safety and access. 
Central to EA is the voluntary involvement of the company 
that manufactures the drug or biologic; without their active 
participation the product cannot be considered for any of the 
processes discussed in this paper. When a physician analyzes 
how best to provide access to investigational drugs, the pathway 
is driven by several factors: (1) the number of patients needing 
access, (2) the time sensitivity of access (emergency or not), 
(3) whether an active IND is in place by which a protocol 
amendment can be fi led or not, (4) whether or not the existing 
IND can be extended to the patient, and (5) availability of an 
IRB with administrative authority and familiarity with the EA 
process. For an individual patient and his or her physician, the 
best course of action is oft en a SP-IND. 
 Another factor relevant to these requests is how the 
infrastructure within a medical center can support the processing 
of such submissions. Availability of a regulatory support offi  ce 
to guide the physician through the SP-IND process is benefi cial 
but not imperative. As outlined above, an individual physician 
has all the information necessary to submit for EA to the FDA 
on his or her own, but many centers do provide support, usually 
without charge. IRBs should be encouraged to develop processes 
to accommodate all forms of EA to investigational drugs. With 
appropriate education, guidance, decision tools and templates, 
IRBs and physicians can become well equipped to manage requests 
for EA. We would encourage such centers to consider waiving 
usual IRB fees for this application unless the volume becomes 
burdensome. Th is is especially appropriate if the manufacturer 
is providing drug at no charge. Equitable access to EA should 
be a consideration as a part of the mission that many serve. For 
physicians not in a relationship with an academic medical center, 
the use of a central IRB can serve that important patient-safeguard 
role. IRB participation is a critical diff erence between EA and 
“Right-to-Try” legislation. 
 “Right-to-Try” legislation is an attempt to expedite the access 
to test agents by creating loopholes to bypass the current federal 
oversight process and IRB or ethics committee review. Th is eff ort 
suggests that members of the general public and some lawmakers 
underappreciate the tenuous nature of drugs in development. 
Very few drugs make it through the entire research pipeline to 
approval for good reason. For investigational products that are 
still in early testing up to and including Phase 3 trials, potential 
adverse events are not known yet, effi  cacy is not established, 
and there is a very real possibility that harm exceeds risk. 
“Right-to-Try” legislation leaves a vulnerable population open 
to unproven and potentially dangerous treatments. Abolishing 
the federal oversight will not solve the dilemma of getting 
investigational products safely to patients more quickly. It seems 
more prudent to arm physicians and their staff  with knowledge 
and skills to meet the existing EA program requirements that 
allow access to investigational agents for seriously ill patients. 
Th e EA program provides a measured approach for access to 
unapproved treatments balanced with a conscious and informed 
consideration of the risks for patient. 
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